Unnamed: 0
int64 0
180k
| text
stringlengths 2
1.45k
| id
int64 0
180k
| label
int64 0
4
|
|---|---|---|---|
900 | Examining participant uptake is important , as evidence suggests that a two-sample FIT may increase the sensitivity to detect CRC . | 900 | 4 |
901 | This study had two objectives : ( i ) to evaluate FIT completion in a population that received either a one-sample FIT kit ( 1-FIT ) or a two-sample FIT kit ( 2-FIT ) and ( ii ) to understand whether uptake varies by age , sex , or receipt of prior CRC screening . | 901 | 0 |
902 | We conducted a randomized controlled trial in which 3081 participants who were aged between 50 and 75 years and were at an average risk for CRC , and who had requested FITs , randomly received 1-FIT ( n = 1540 ) or 2-FIT ( n = 1541 ) kits . | 902 | 1 |
903 | FIT completion was defined as the completion and return of a one-sample test by the patients in the 1-FIT group or of both sample tests by those in the 2-FIT group . | 903 | 1 |
904 | Cox proportional hazard regression models were used to determine the independent effect of group type ( 2-FIT vs. 1-FIT ) on the completion of the FIT , adjusting for age , sex , and receipt of prior CRC screening . | 904 | 1 |
905 | The 2-FIT group had lower test completion rates ( hazard ratio = 0.87 ; 95 % confidence interval = 0.78-0 .97 ; P = 0.01 ) after adjusting for age , sex , and receipt of prior CRC screening . | 905 | 2 |
906 | Participant uptake did not vary by age , sex , or receipt of prior CRC screening . | 906 | 2 |
907 | This unique , rigorous randomized controlled trial found that the 2-FIT regimen decreases completion of FIT . | 907 | 3 |
908 | Further research is needed to understand whether decreases in participant uptake are offset by increased gains in test sensitivity . | 908 | 3 |
909 | Evaluation of the safety and efficacy of pazopanib , a multikinase angiogenesis inhibitor , in a single-arm , open-label , extension study ( VEG107769/NCT00387764 ) for placebo-treated patients with advanced renal cell carcinoma ( RCC ) from a randomized , double-blind , placebo-controlled phase III study ( VEG105192/NCT00334282 ) . | 909 | 0 |
910 | Patients received pazopanib 800 mg/day . | 910 | 1 |
911 | The primary endpoint was the safety and tolerability of pazopanib treatment . | 911 | 1 |
912 | Secondary endpoints included response rate per Response Evaluation Criteria in Solid Tumors , progression-free survival ( PFS ) , and overall survival ( OS ) . | 912 | 1 |
913 | Seventy-nine placebo-treated patients from VEG105192/NCT00334282 who experienced disease progression and one pazopanib-treated patient ( an exemption ) were enrolled . | 913 | 2 |
914 | Forty-one patients ( 51 % ) were treatment-naive ; 39 ( 49 % ) were cytokine-pretreated . | 914 | 2 |
915 | Median exposure to pazopanib was 9.7 months . | 915 | 2 |
916 | All patients had discontinued pazopanib at the time of analysis . | 916 | 2 |
917 | The most common reason for discontinuation was disease progression ( 61 % ) . | 917 | 2 |
918 | The most common adverse events were hypertension ( 45 % ) , diarrhea ( 45 % ) , hair color changes ( 44 % ) , anorexia ( 30 % ) , and nausea ( 25 % ) . | 918 | 2 |
919 | The response rate was 37.5 % [ 95 % confidence interval ( CI ) : 26.9-48 .1 ] ; median PFS was 9.2 months ( 95 % CI : 7.3-12 .0 ) ; median OS was 23.5 months ( 95 % CI : 16.3-28 .0 ) . | 919 | 2 |
920 | Efficacy and safety profiles for pazopanib in this extension study of patients with RCC previously treated with placebo were very similar to those observed for pazopanib-treated patients in the pivotal phase III study . | 920 | 3 |
921 | An established multivariate serum protein test can be used to classify patients according to whether they are likely to have a good or poor outcome after treatment with EGFR tyrosine-kinase inhibitors . | 921 | 4 |
922 | We assessed the predictive power of this test in the comparison of erlotinib and chemotherapy in patients with non-small-cell lung cancer . | 922 | 4 |
923 | From Feb 26 , 2008 , to April 11 , 2012 , patients ( aged 18 years ) with histologically or cytologically confirmed , second-line , stage IIIB or IV non-small-cell lung cancer were enrolled in 14 centres in Italy . | 923 | 1 |
924 | Patients were stratified according to a minimisation algorithm by Eastern Cooperative Oncology Group performance status , smoking history , centre , and masked pretreatment serum protein test classification , and randomly assigned centrally in a 1:1 ratio to receive erlotinib ( 150 mg/day , orally ) or chemotherapy ( pemetrexed 500 mg/m ( 2 ) , intravenously , every 21 days , or docetaxel 75 mg/m ( 2 ) , intravenously , every 21 days ) . | 924 | 1 |
925 | The proteomic test classification was masked for patients and investigators who gave treatments , and treatment allocation was masked for investigators who generated the proteomic classification . | 925 | 1 |
926 | The primary endpoint was overall survival and the primary hypothesis was the existence of a significant interaction between the serum protein test classification and treatment . | 926 | 1 |
927 | Analyses were done on the per-protocol population . | 927 | 1 |
928 | This trial is registered with ClinicalTrials.gov , number NCT00989690 . | 928 | 1 |
929 | 142 patients were randomly assigned to chemotherapy and 143 to erlotinib , and 129 ( 91 % ) and 134 ( 94 % ) , respectively , were included in the per-protocol analysis . | 929 | 2 |
930 | 88 ( 68 % ) patients in the chemotherapy group and 96 ( 72 % ) in the erlotinib group had a proteomic test classification of good . | 930 | 2 |
931 | Median overall survival was 90 months ( 95 % CI 68-109 ) in the chemotherapy group and 77 months ( 59-104 ) in the erlotinib group . | 931 | 2 |
932 | We noted a significant interaction between treatment and proteomic classification ( pinteraction = 0017 when adjusted for stratification factors ; pinteraction = 0031 when unadjusted for stratification factors ) . | 932 | 2 |
933 | Patients with a proteomic test classification of poor had worse survival on erlotinib than on chemotherapy ( hazard ratio 172 [ 95 % CI 108-274 ] , p = 0022 ) . | 933 | 2 |
934 | There was no significant difference in overall survival between treatments for patients with a proteomic test classification of good ( adjusted HR 106 [ 077-146 ] , p = 0714 ) . | 934 | 2 |
935 | In the group of patients who received chemotherapy , the most common grade 3 or 4 toxic effect was neutropenia ( 19 [ 15 % ] vs one [ < 1 % ] in the erlotinib group ) , whereas skin toxicity ( one [ < 1 % ] vs 22 [ 16 % ] ) was the most frequent in the erlotinib group . | 935 | 2 |
936 | Our findings indicate that serum protein test status is predictive of differential benefit in overall survival for erlotinib versus chemotherapy in the second-line setting . | 936 | 3 |
937 | Patients classified as likely to have a poor outcome have better outcomes on chemotherapy than on erlotinib . | 937 | 3 |
938 | Italian Ministry of Health , Italian Association of Cancer Research , and Biodesix . | 938 | 4 |
939 | This study was to evaluate the effect of intraoperative continuous infusion of dexmedetomidine on intraocular pressure ( IOP ) in patients undergoing robot-assisted laparoscopic radical prostatectomy ( RALRP ) in the steep Trendelenburg ( ST ) . | 939 | 0 |
940 | Sixty-eight patients were randomly divided into two groups . | 940 | 1 |
941 | The dexmedetomidine group ( Group D , n = 34 ) received a continuous infusion of dexmedetomidine at a rate of 0.4 g kg ( -1 ) hour ( -1 ) from the induction of anesthesia until the end of the ST position , while the control group ( Group C , n = 34 ) received an equal volume of physiologic saline at the same rate under conventional general anesthesia with sevoflurane and remifentanil . | 941 | 1 |
942 | IOP was measured at 11 predefined time points for all patients . | 942 | 1 |
943 | Significant differences in IOP were detected between the two groups by a linear mixed model analysis ( p < 0.001 ) . | 943 | 2 |
944 | The highest mean IOP was 19.95.0 mm Hg in Group D and 25.75.0 mm Hg in Group C ; both were measured 60 minutes after the patients had been placed in the ST position . | 944 | 2 |
945 | No significant between-group differences in ocular perfusion pressure , mean blood pressure , or heart rate were observed between the two groups . | 945 | 2 |
946 | No ocular or other complications were noted . | 946 | 2 |
947 | Intraoperative continuous infusion of dexmedetomidine may help alleviate IOP increase in patients undergoing RALRP in the ST position . | 947 | 3 |
948 | Disruptive or challenging behavior problems pose a threat to children and adolescents with intellectual disabilities and their caregivers . | 948 | 0 |
949 | Psychopharmacological treatment is mostly studied with new-generation antipsychotics and has been criticized for adverse side effects . | 949 | 0 |
950 | This study examined the effect of the classic antipsychotic zuclopenthixol . | 950 | 0 |
951 | A total of 39 boys ( ages 8.0-17 .11 years ) with learning disabilities were included and examined for a response to zuclopenthixol during a 6 week period of open label treatment . | 951 | 1 |
952 | Doses started low and were adapted individually . | 952 | 1 |
953 | From responders , zuclopenthixol was randomly withdrawn for 12 weeks . | 953 | 1 |
954 | Responses to withdrawal were observed by external raters using the Modified Overt Aggression Scale . | 954 | 1 |
955 | Of all patients included into the study , 15 were not randomized because of insufficient therapeutic effect , adverse event , or noncompliance . | 955 | 2 |
956 | Kaplan-Meier estimations showed less aggressive behavior problems for the continuing subgroup ( n = 9 ) than in the placebo group ( n = 15 ) . | 956 | 2 |
957 | Individual doses stayed < 10mg/day . | 957 | 2 |
958 | Zuclopenthixol proved to be effective in reducing challenging behavior in boys even at low doses . | 958 | 3 |
959 | The purpose of this multicenter , open label , randomized phase III study was to determine whether ixabepilone resulted in improved overall survival ( OS ) compared with commonly used single-agent chemotherapy ( doxorubicin or paclitaxel ) in women with locally advanced , recurrent , or metastatic endometrial cancer with at least one failed prior platinum-based chemotherapeutic regimen . | 959 | 0 |
960 | Patients were randomized 1:1 to ixabepilone ( 40mg/m ( 2 ) ) , or either paclitaxel ( 175mg/m ( 2 ) ) or doxorubicin ( 60mg/m ( 2 ) ) , every 21days . | 960 | 1 |
961 | Patients that had previously received an anthracycline were randomized to ixabepilone or paclitaxel ; all other patients were randomized to ixabepilone or doxorubicin . | 961 | 1 |
962 | An interim analysis of futility for OS was planned . | 962 | 1 |
963 | At the time of database lock , 496 patients were randomized to receive ixabepilone ( n = 248 ) or control ( n = 248 ) ; nine patients in the control arm were not treated . | 963 | 2 |
964 | The interim analysis of futility for OS ( 219 events ) favored the control chemotherapy arm ( hazard ratio = 1.3 [ 95 % confidence interval : 1.0-1 .7 ] , stratified log rank test P = 0.0397 ) , indicating that the study would not meet its primary objective . | 964 | 2 |
965 | The study was discontinued based on the interim OS results . | 965 | 2 |
966 | The frequency of adverse events was comparable between the treatment arms . | 966 | 2 |
967 | The study did not meet its primary objective of improving OS in the ixabepilone arm compared to the control chemotherapy arm . | 967 | 3 |
968 | A favorable risk/benefit ratio was not observed for ixabepilone versus control at the time of the interim analysis . | 968 | 3 |
969 | The safety results were consistent with the known safety profiles of ixabepilone and control . | 969 | 3 |
970 | To determine the impact of calcium and phosphorus on radiological and biochemical characteristics of osteopenia in premature infants . | 970 | 0 |
971 | The randomised clinical trial study was conducted at Valie-e-Asr Hospital of Zanjan city , Iran , from December 2010 to June 2011 . | 971 | 1 |
972 | It involved monitoring 40 premature neonates over a period of six months . | 972 | 1 |
973 | The babies , who were fed with breast milk and 400 units of vitamin D daily , were randomly divided into two equal groups . | 973 | 1 |
974 | One group received supplement of calcium and phosphorus . | 974 | 1 |
975 | Serum calcium , phosphorus and alkaline phosphatase levels as well as growth parameters ( including weight , height , and head circumference ) were measured every two weeks . | 975 | 1 |
976 | At the end of the study , wrist X-ray was done for evaluation of osteopenia . | 976 | 1 |
977 | Data was analysed using SPSS 16 . | 977 | 1 |
978 | Radiological changes , characteristic of osteopenia , were found in 8 ( 40 % ) cases and 13 ( 65 % ) controls ( p < 0.113 ) . | 978 | 2 |
979 | The mean of weight , length and head circumference increased significantly from second to sixth week during follow-up ( p < 0.0001 ) . | 979 | 2 |
980 | Phosphorus and alkaline phosphatase activity decreased significantly from second to sixth week of follow-up ( p < 0.02 , p < 0.01 respectively ) . | 980 | 2 |
981 | However , repeated measurement analyses did not show significant effect of intervention in biochemical and growth parameters in the trial group . | 981 | 2 |
982 | The study did n't show significant effect of calcium and phosphorus on prevention of osteopenia and improvement of growth . | 982 | 3 |
983 | Further studies of longer duration and with different doses of supplement are recommended . | 983 | 3 |
984 | The purpose of this study was to test the efficacy of a 6-month course of anti-inflammatory treatment with colchicinein improving functional status of patients with stable chronic heart failure ( CHF ) . | 984 | 0 |
985 | CHF has been shown to be associated with inflammatory activation . | 985 | 4 |
986 | Inflammation has been designated as a therapeutic target in CHF . | 986 | 4 |
987 | Patients with stable CHF were randomly assigned to colchicine ( 0.5 mg twice daily ) or placebo for 6 months . | 987 | 1 |
988 | Theprimary endpoint was the proportion of patients achieving at least one-grade improvement in New York HeartAssociation class . | 988 | 1 |
989 | Two hundred sixty-seven patients were available for final evaluation of the primary endpoint : its rate was 11 % in the control group and 14 % in the colchicine group ( odds ratio : 1.40 ; 95 % confidence interval : 0.67 to 2.93 ; p = 0.365 ) . | 989 | 2 |
990 | The rate of the composite of death or hospital stay for heart failure was 9.4 % in the control group , compared with 10.1 % in the colchicine group ( p = 0.839 ) . | 990 | 2 |
991 | The changes in treadmill exercise time with treatment were insignificant and similar in the 2 groups ( p = 0.938 ) . | 991 | 2 |
992 | C-reactive protein and interleukin-6 were both significantly reduced in the colchicine group ( -5.1 mg/l and -4.8 pg/ml , respectively ; p < 0.001 for both , compared with the control group ) . | 992 | 2 |
993 | According to this prospective , randomized study , anti-inflammatory treatment with colchicine in patients with stable CHF , although effective in reducing inflammation biomarker levels , did not affect in any significant way patient functional status ( in terms of New York Heart Association class and objective treadmill exercise tolerance ) or the likelihood of death or hospital stay for heart failure . | 993 | 3 |
994 | To examine the comparative antidepressant efficacy of S-adenosyl-L-methionine ( SAMe ) and escitalopram in a placebo-controlled , randomized , double-blind clinical trial . | 994 | 0 |
995 | One hundred eighty-nine outpatients ( 49.7 % female , mean [ SD ] age = 45 [ 15 ] years ) with DSM-IV-diagnosed major depressive disorder ( MDD ) were recruited from April 13 , 2005 , to December 22 , 2009 , at the Massachusetts General Hospital and at Butler Hospital . | 995 | 1 |
996 | Patients were randomized for 12 weeks to SAMe 1,600-3 ,200 mg/d , escitalopram 10-20 mg/d , or placebo . | 996 | 1 |
997 | Doses were escalated at 6 weeks in the event of nonresponse . | 997 | 1 |
998 | The main outcome measure was the 17-item Hamilton Depression Rating Scale ( HDRS-17 ) . | 998 | 1 |
999 | Tolerability was assessed by the Systematic Assessment for Treatment of Emergent Events-Specific Inquiry ( SAFTEE-SI ) . | 999 | 1 |
Subsets and Splits